"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thiohydantoin benzene derivative.
| Descriptor ID |
D010669
|
| MeSH Number(s) |
D03.383.129.308.432.555.868.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".
Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".
This graph shows the total number of publications written about "Phenylthiohydantoin" by people in this website by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.
-
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
-
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 Apr 02; 23(4):552-563.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869.
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622.
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282.